(MMS) Maximus - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US5779331041
Stock: Eligibility, Enrollment, Assessments, Contact Centers, Technology
Total Rating 42
Risk 95
Buy Signal -0.71
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.58% |
| Yield on Cost 5y | 2.00% |
| Yield CAGR 5y | 1.74% |
| Payout Consistency | 96.8% |
| Payout Ratio | 16.1% |
| Risk 5d forecast | |
|---|---|
| Volatility | 36.2% |
| Relative Tail Risk | -13.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.30 |
| Alpha | -8.68 |
| Character TTM | |
|---|---|
| Beta | 0.447 |
| Beta Downside | 0.413 |
| Drawdowns 3y | |
|---|---|
| Max DD | 30.37% |
| CAGR/Max DD | -0.07 |
Description: MMS Maximus January 10, 2026
Maximus, Inc. (NYSE:MMS) delivers outsourced government services across three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The Federal segment provides business-process outsourcing, eligibility and enrollment, clinical and technology solutions-including analytics, cybersecurity, and cloud modernization-for health and human-services programs. The U.S. Services segment focuses on eligibility support, multilingual contact centers, benefit counseling, and employment-service programs, while the Outside-the-U.S. segment offers similar BPS and technology offerings to international governments.
Key operating metrics that analysts watch include the company’s FY 2023 revenue of approximately $4.5 billion, up roughly 7 % YoY, driven largely by a 12 % increase in the Federal Services backlog. Gross margins have hovered near 24 %, reflecting the higher-margin technology and analytics contracts. A material macro driver is the U.S. federal budget outlook-particularly Medicaid and SNAP spending-which historically accounts for about 70 % of Maximus’ revenue and can swing earnings materially.
For a deeper dive into Maximus’ valuation metrics and peer comparison, the ValueRay platform offers a concise data sheet worth reviewing.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 371.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -1.72 > 1.0 |
| NWC/Revenue: 15.17% < 20% (prev 9.04%; Δ 6.13% < -1%) |
| CFO/TA 0.06 > 3% & CFO 265.0m > Net Income 371.8m |
| Net Debt (1.60b) to EBITDA (732.2m): 2.18 < 3 |
| Current Ratio: 2.34 > 1.5 & < 3 |
| Outstanding Shares: last quarter (55.3m) vs 12m ago -7.84% < -2% |
| Gross Margin: 23.85% > 18% (prev 0.22%; Δ 2363 % > 0.5%) |
| Asset Turnover: 130.0% > 50% (prev 132.6%; Δ -2.60% > 0%) |
| Interest Coverage Ratio: 6.97 > 6 (EBITDA TTM 732.2m / Interest Expense TTM 85.7m) |
Altman Z'' 3.83
| A: 0.19 (Total Current Assets 1.42b - Total Current Liabilities 608.0m) / Total Assets 4.21b |
| B: 0.26 (Retained Earnings 1.11b / Total Assets 4.21b) |
| C: 0.14 (EBIT TTM 596.8m / Avg Total Assets 4.13b) |
| D: 0.69 (Book Value of Equity 1.72b / Total Liabilities 2.49b) |
| Altman-Z'' Score: 3.83 = AA |
Beneish M -2.97
| DSRI: 1.19 (Receivables 1.15b/964.0m, Revenue 5.37b/5.38b) |
| GMI: 0.91 (GM 23.85% / 21.59%) |
| AQI: 0.93 (AQ_t 0.62 / AQ_t-1 0.67) |
| SGI: 1.00 (Revenue 5.37b / 5.38b) |
| TATA: 0.03 (NI 371.8m - CFO 265.0m) / TA 4.21b) |
| Beneish M-Score: -2.97 (Cap -4..+1) = A |
What is the price of MMS shares?
As of February 09, 2026, the stock is trading at USD 75.08 with a total of 1,786,384 shares traded.
Over the past week, the price has changed by -20.55%, over one month by -20.90%, over three months by -9.29% and over the past year by +9.43%.
Over the past week, the price has changed by -20.55%, over one month by -20.90%, over three months by -9.29% and over the past year by +9.43%.
Is MMS a buy, sell or hold?
Maximus has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy MMS.
- StrongBuy: 0
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MMS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 110 | 46.5% |
| Analysts Target Price | 110 | 46.5% |
| ValueRay Target Price | 77.6 | 3.3% |
MMS Fundamental Data Overview February 08, 2026
P/E Trailing = 11.5153
P/E Forward = 18.2482
P/S = 0.7621
P/B = 2.481
P/EG = 2.0716
Revenue TTM = 5.37b USD
EBIT TTM = 596.8m USD
EBITDA TTM = 732.2m USD
Long Term Debt = 1.28b USD (from longTermDebt, last fiscal year)
Short Term Debt = 95.8m USD (from shortTermDebt, last quarter)
Debt = 1.74b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.60b USD (from netDebt column, last quarter)
Enterprise Value = 5.69b USD (4.10b + Debt 1.74b - CCE 137.6m)
Interest Coverage Ratio = 6.97 (Ebit TTM 596.8m / Interest Expense TTM 85.7m)
EV/FCF = 26.06x (Enterprise Value 5.69b / FCF TTM 218.5m)
FCF Yield = 3.84% (FCF TTM 218.5m / Enterprise Value 5.69b)
FCF Margin = 4.07% (FCF TTM 218.5m / Revenue TTM 5.37b)
Net Margin = 6.92% (Net Income TTM 371.8m / Revenue TTM 5.37b)
Gross Margin = 23.85% ((Revenue TTM 5.37b - Cost of Revenue TTM 4.09b) / Revenue TTM)
Gross Margin QoQ = 23.69% (prev 23.55%)
Tobins Q-Ratio = 1.35 (Enterprise Value 5.69b / Total Assets 4.21b)
Interest Expense / Debt = 1.10% (Interest Expense 19.1m / Debt 1.74b)
Taxrate = 25.60% (32.3m / 126.3m)
NOPAT = 444.0m (EBIT 596.8m * (1 - 25.60%))
Current Ratio = 2.34 (Total Current Assets 1.42b / Total Current Liabilities 608.0m)
Debt / Equity = 1.01 (Debt 1.74b / totalStockholderEquity, last quarter 1.72b)
Debt / EBITDA = 2.18 (Net Debt 1.60b / EBITDA 732.2m)
Debt / FCF = 7.31 (Net Debt 1.60b / FCF TTM 218.5m)
Total Stockholder Equity = 1.71b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.99% (Net Income 371.8m / Total Assets 4.21b)
RoE = 21.76% (Net Income TTM 371.8m / Total Stockholder Equity 1.71b)
RoCE = 19.96% (EBIT 596.8m / Capital Employed (Equity 1.71b + L.T.Debt 1.28b))
RoIC = 13.88% (NOPAT 444.0m / Invested Capital 3.20b)
WACC = 5.55% (E(4.10b)/V(5.83b) * Re(7.56%) + D(1.74b)/V(5.83b) * Rd(1.10%) * (1-Tc(0.26)))
Discount Rate = 7.56% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -5.20%
[DCF Debug] Terminal Value 85.80% ; FCFF base≈243.4m ; Y1≈231.0m ; Y5≈220.4m
Fair Price DCF = 91.96 (EV 6.61b - Net Debt 1.60b = Equity 5.02b / Shares 54.5m; r=5.90% [WACC]; 5y FCF grow -6.60% → 2.90% )
EPS Correlation: 83.53 | EPS CAGR: 25.05% | SUE: 0.37 | # QB: 0
Revenue Correlation: 86.08 | Revenue CAGR: 3.62% | SUE: -0.72 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.04 | Chg30d=+0.020 | Revisions Net=+0 | Analysts=2
EPS current Year (2026-09-30): EPS=8.52 | Chg30d=+0.345 | Revisions Net=+2 | Growth EPS=+15.7% | Growth Revenue=-0.6%
EPS next Year (2027-09-30): EPS=9.12 | Chg30d=+0.435 | Revisions Net=+2 | Growth EPS=+7.0% | Growth Revenue=+5.2%
P/E Forward = 18.2482
P/S = 0.7621
P/B = 2.481
P/EG = 2.0716
Revenue TTM = 5.37b USD
EBIT TTM = 596.8m USD
EBITDA TTM = 732.2m USD
Long Term Debt = 1.28b USD (from longTermDebt, last fiscal year)
Short Term Debt = 95.8m USD (from shortTermDebt, last quarter)
Debt = 1.74b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.60b USD (from netDebt column, last quarter)
Enterprise Value = 5.69b USD (4.10b + Debt 1.74b - CCE 137.6m)
Interest Coverage Ratio = 6.97 (Ebit TTM 596.8m / Interest Expense TTM 85.7m)
EV/FCF = 26.06x (Enterprise Value 5.69b / FCF TTM 218.5m)
FCF Yield = 3.84% (FCF TTM 218.5m / Enterprise Value 5.69b)
FCF Margin = 4.07% (FCF TTM 218.5m / Revenue TTM 5.37b)
Net Margin = 6.92% (Net Income TTM 371.8m / Revenue TTM 5.37b)
Gross Margin = 23.85% ((Revenue TTM 5.37b - Cost of Revenue TTM 4.09b) / Revenue TTM)
Gross Margin QoQ = 23.69% (prev 23.55%)
Tobins Q-Ratio = 1.35 (Enterprise Value 5.69b / Total Assets 4.21b)
Interest Expense / Debt = 1.10% (Interest Expense 19.1m / Debt 1.74b)
Taxrate = 25.60% (32.3m / 126.3m)
NOPAT = 444.0m (EBIT 596.8m * (1 - 25.60%))
Current Ratio = 2.34 (Total Current Assets 1.42b / Total Current Liabilities 608.0m)
Debt / Equity = 1.01 (Debt 1.74b / totalStockholderEquity, last quarter 1.72b)
Debt / EBITDA = 2.18 (Net Debt 1.60b / EBITDA 732.2m)
Debt / FCF = 7.31 (Net Debt 1.60b / FCF TTM 218.5m)
Total Stockholder Equity = 1.71b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.99% (Net Income 371.8m / Total Assets 4.21b)
RoE = 21.76% (Net Income TTM 371.8m / Total Stockholder Equity 1.71b)
RoCE = 19.96% (EBIT 596.8m / Capital Employed (Equity 1.71b + L.T.Debt 1.28b))
RoIC = 13.88% (NOPAT 444.0m / Invested Capital 3.20b)
WACC = 5.55% (E(4.10b)/V(5.83b) * Re(7.56%) + D(1.74b)/V(5.83b) * Rd(1.10%) * (1-Tc(0.26)))
Discount Rate = 7.56% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -5.20%
[DCF Debug] Terminal Value 85.80% ; FCFF base≈243.4m ; Y1≈231.0m ; Y5≈220.4m
Fair Price DCF = 91.96 (EV 6.61b - Net Debt 1.60b = Equity 5.02b / Shares 54.5m; r=5.90% [WACC]; 5y FCF grow -6.60% → 2.90% )
EPS Correlation: 83.53 | EPS CAGR: 25.05% | SUE: 0.37 | # QB: 0
Revenue Correlation: 86.08 | Revenue CAGR: 3.62% | SUE: -0.72 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.04 | Chg30d=+0.020 | Revisions Net=+0 | Analysts=2
EPS current Year (2026-09-30): EPS=8.52 | Chg30d=+0.345 | Revisions Net=+2 | Growth EPS=+15.7% | Growth Revenue=-0.6%
EPS next Year (2027-09-30): EPS=9.12 | Chg30d=+0.435 | Revisions Net=+2 | Growth EPS=+7.0% | Growth Revenue=+5.2%